Cancer remains the leading cause of disease-related death in American children, yet a new presidential initiative aims to harness artificial intelligence to change that grim statistic.
The newly established Make America Healthy Again (MAHA) Commission will coordinate with federal health agencies to leverage AI technologies specifically for pediatric cancer research and care, according to an executive order signed by the President on September 30. The commission’s mandate? Develop innovative approaches using advanced technologies to improve diagnosis, treatment, and prevention strategies for childhood cancers.
A Growing Threat to America’s Children
The stakes couldn’t be higher. Pediatric cancer’s incidence has increased by more than 40 percent since 1975, with an estimated 9,550 new cases expected to be diagnosed among children from birth to 14 years in 2025. About 1,050 children are expected to die from the disease this year alone.
What’s behind these numbers? Despite significant progress in treatment — childhood cancer death rates have declined by 70% from 1970 to 2020 — cancer remains stubbornly entrenched as the top disease-related killer of American kids.
“Each year, the parents of more than 15,000 children age 0-19 in the U.S. will hear the words ‘your child has cancer,'” notes CureSearch for Children’s Cancer. “Across all ages, ethnic groups, and socio-economics, this disease remains the number one cause of death by disease in children.”
AI’s Role in the Fight
The executive order directs the MAHA Commission to pursue several AI-focused initiatives, including improving data infrastructure, enhancing AI-based analysis of biological data, and optimizing clinical trial design. One key aspect involves consolidating multiple data sources to create AI-ready datasets for researchers.
But how exactly will AI make a difference? The order specifies that the Secretary, in consultation with the Assistant to the President for Science and Technology, “shall work to ensure that AI innovation is appropriately integrated into current work on interoperability to maximize the potential for electronic health record and claims data to inform private sector and academic research and clinical trial design.”
This builds upon existing efforts. The U.S. government had previously created the Childhood Cancer Data Initiative (CCDI) with $50 million in annual funding over 10 years to collect, generate, and analyze childhood cancer data. The new executive order aims to accelerate these efforts through artificial intelligence.
Progress and Challenges
There’s reason for cautious optimism. While childhood cancer remains deadly, survival rates have improved dramatically over the past four decades. Currently, about 85% of children diagnosed with cancer in the United States survive at least five years after diagnosis, a significant improvement from just 10% in the early 1970s.
That survival, however, often comes at a cost. Many of the estimated 483,000 adult survivors of childhood cancer face chronic health issues resulting from their treatments. These “late effects” can include heart problems, secondary cancers, and cognitive impairments.
The new AI initiatives aim to address these challenges by developing more precise treatments with fewer side effects. By analyzing vast amounts of biological data, including multi-omics information and imaging, researchers hope to develop novel biomarkers that could lead to more targeted therapies.
Data Privacy Concerns
Will parents be comfortable sharing their children’s sensitive medical data? The executive order addresses this concern head-on, emphasizing that patients and parents must retain control over their health information while enabling the data sharing necessary for AI-powered research.
The initiative calls for creating standards to safely exchange both structured and unstructured health data, a technical challenge that has hampered previous efforts to consolidate medical information across institutions.
Despite diagnosis rates that haven’t decreased significantly in nearly two decades, the integration of AI into pediatric cancer research represents a new frontier in the fight against this persistent threat to America’s children. For the thousands of families who will face a childhood cancer diagnosis this year, these technological advances can’t come soon enough.
